39.23
0.18 (0.46%)
Penutupan Terdahulu | 39.05 |
Buka | 38.41 |
Jumlah Dagangan | 668,888 |
Purata Dagangan (3B) | 578,058 |
Modal Pasaran | 2,272,013,312 |
Harga / Pendapatan (P/E TTM) | 3.40 |
Harga / Jualan (P/S) | 61.32 |
Harga / Buku (P/B) | 1.54 |
Julat 52 Minggu | |
Tarikh Pendapatan | 31 Jul 2025 |
Margin Keuntungan | 1,798.26% |
Margin Operasi (TTM) | -1,221.97% |
EPS Cair (TTM) | 11.54 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 6.60% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 3.61% |
Nisbah Semasa (MRQ) | 18.50 |
Aliran Tunai Operasi (OCF TTM) | -401.46 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -237.66 M |
Pulangan Atas Aset (ROA TTM) | -22.88% |
Pulangan Atas Ekuiti (ROE TTM) | 60.26% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Agios Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 1.5 |
Aktiviti Orang Dalam | -3.0 |
Volatiliti Harga | -1.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | -0.10 |
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 1.65% |
% Dimiliki oleh Institusi | 101.39% |
Julat 52 Minggu | ||
Median | 71.00 (80.98%) | |
Jumlah | 1 Beli |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Scotiabank | 02 May 2025 | 71.00 (80.98%) | Beli | 30.10 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |